Post-Chemotherapeutic Administration of Interleukin-12 Retards Tumor Growth and Enhances Immune Cell Function: Combination Therapy Using Paclitaxel and IL-12

Author： Pressley Jennifer   Elgert Klaus  

Publisher： Informa Healthcare

ISSN： 0735-7907

Source： Cancer Investigation, Vol.24, Iss.4, 2006-07, pp. : 351-359

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse

By Vicari Alain  

Cancer Immunology, Immunotherapy, Vol. 58, Iss. 4, 2009-04 ,pp. : 615-628

Springer Publishing Company

Access to resources Recommend Favorite

Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation

By Pauwels Bea   Wouters An   Peeters Marc   Vermorken Jan B   Lardon Filip  

Future Oncology, Vol. 6, Iss. 9, 2010-09 ,pp. : 1485-1496

Future Medicine

Access to resources Recommend Favorite

An oncolytic adenovirus expressing interleukin-24 enhances antitumor activities in combination with paclitaxel in breast cancer cells

By              

Molecular Medicine Reports, Vol. 8, Iss. 5, 2013-01 ,pp. : 1416-1424

Spandidos Publications

Access to resources Recommend Favorite

Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice

By Allegrini Giacomo   Goulette Frederick   Darnowski James   Calabresi Paul  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 3, 2004-03 ,pp. : 261-266

Springer Publishing Company

Access to resources Recommend Favorite

IL-12 as an adjuvant for cell-mediated immunity

By Scott P.   Trinchieri G.  

Seminars in Immunology, Vol. 9, Iss. 5, 1997-10 ,pp. : 285-291

Academic Press

Access to resources Recommend Favorite